

Development and Optimization of Novel Drug Delivery Systems for Targeted Therapy: An Analytical Perspective:

Komal Chandra,

Asst. Professor, School of Pharmacy, Graphic Era Hill University,
Dehradun, Uttarakhand India 248002

DOI:10.48047/ejmcm/v05/i01/75

Abstract

A promising strategy in the realm of pharmaceutical research is the creation and improvement of new drug delivery systems for targeted therapy. Targeted therapy tries to deliver therapeutic medicines to cells or tissues selectively, reducing systemic side effects and increasing treatment effectiveness. To improve the targeting capacities of drug delivery systems, several ways have been investigated. These include using ligands, antibodies, peptides, or nanoparticles to recognize and bind to target cells or tissues in a targeted manner. The development of nanoparticles with distinctive physicochemical properties that can more precisely and effectively encapsulate and distribute medicinal medicines to target areas is another result of breakthroughs in nanotechnology. The stability, drug loading capacity, release kinetics, and biocompatibility of drug delivery systems have all been improved with the help of optimization techniques. A controlled-release system that reacts to triggers, such as pH, temperature, or enzyme activity, has been developed because of the incorporation of smart materials, such as stimuli-responsive polymers and nanogels. These developments offer hope for the treatment of numerous illnesses, including as cancer, cardiovascular problems, and neurodegenerative issues, by improving medicine efficacy and reducing side effects. To transfer these novel techniques into practical applications and enhance patient outcomes, more study and cooperation amongst multidisciplinary teams are required.

Keywords: Nanoparticles, Controlled release, Active targeting, Stability, Biocompatibility.

Introduction:

Medical practice has undergone a revolution, especially in targeted therapy, because of the creation and improvement of innovative drug delivery methods. To maximize effectiveness while minimizing negative side effects on healthy tissues, targeted therapy seeks to deliver therapeutic molecules to cells, tissues, or organs. This strategy has a great deal of potential for the treatment of numerous illnesses, such as cancer, cardiovascular problems, neurological illnesses, and

autoimmune disorders. Poor bioavailability, a lack of specificity, a lack of stability, and insufficient control over drug release are common problems with traditional drug delivery systems. Due to these restrictions, researchers are investigating novel methods to improve drug delivery and boost therapeutic results. Significant progress has been made recently in the creation of innovative drug delivery systems that may precisely target diseased tissues or cells, provide therapeutic chemicals in a regulated manner, and enhance treatment effectiveness **(Ojewole et al. 2008)**. The utilization of nanotechnology-based medication delivery systems is one of the most promising strategies in targeted medicine. Due to the small size and high surface area-to-volume ratio, nanoparticles, which are typically 1 to 100 nanometers in size, have special advantages. These characteristics allow for the effective encapsulation, defense, and controlled release of medicinal substances. Numerous forms of nanoparticles, including liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, have been thoroughly studied for applications in targeted therapy. As medication transporters, vesicles made of lipid called liposomes have drawn a lot of attention. Within the watery core and lipid bilayer, they can contain both hydrophilic and hydrophobic medications. Targeting ligands can be added to liposomes' surface to enable them to recognize and bind to receptors that are overexpressed on sick cells. By selectively accumulating therapeutic molecules at the appropriate region, this active targeting strategy reduces off-target effects. Polymeric nanoparticles are becoming increasingly popular as adaptable medication delivery methods. By adjusting the polymer composition, molecular weight, and surface changes, these nanoparticles can be engineered to produce the desired drug release kinetics. Small molecules, proteins, peptides, and nucleic acids are just a few of the many medications that can be packaged into polymeric nanoparticles **(Anselmo, A. C., & Mitragotri, S. 2014)**.

Another option for focused therapy is provided by dendrimers, which are highly branched macromolecules. Size, shape, and surface capabilities are all be precisely under control. Drugs can either be conjugated to the surface of dendrimers or encapsulated within the cavities. Dendrimer surfaces that have been functionalized allow for more precise targeting and easier passage across biological barriers. Dendrimers have also demonstrated the ability to deliver numerous medicines simultaneously, which can work in concert to affect various targets or pathways to produce stronger therapeutic effects. The unique physicochemical characteristics of metallic nanoparticles, such as gold nanoparticles and magnetic nanoparticles, have attracted

attention. Gold nanoparticles can be used for targeted medication delivery and imaging because of the high biocompatibility, simplicity in manufacturing, and surface plasmon resonance (**Tacar et al. 2013; Alam et al., 2017**).

Literature Review:

To increase the effectiveness and lessen the negative effects of traditional medicines, targeted therapy has become a promising strategy in the field of drug delivery. On the creation and improvement of innovative drug delivery systems for targeted therapy, significant research efforts is done throughout the years. By increasing the selectivity and specificity of therapeutic activity, targeted therapy provides important advantages over traditional drug delivery techniques. Therapeutic chemicals are delivered directly to the target region, decreasing systemic exposure and off-target consequences.

Nanoparticles as Drug Delivery Systems: Due to the distinctive characteristics and powers, nanoparticles have become viable medication delivery methods. They can interact with biological systems at the cellular and molecular levels since they are extremely small particles with sizes ranging from 1 to 100 nanometers. Biocompatible and biodegradable polymers like poly (lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and chitosan make up polymeric nanoparticles. Small compounds, proteins, and nucleic acids are just a few of the many medications that these nanoparticles can enclose. They have several benefits, including high drug-loading capacity, prolonged release kinetics, and defense against drug degradation. For improved targeting of cells or tissues, the surfaces of polymeric nanoparticles can be modified with ligands or antibodies. Metal-based nanoparticles with distinctive physicochemical features, such gold, silver, and iron oxide nanoparticles, are desirable for drug delivery applications. With careful control over the size, shape, and surface characteristics, they can be synthesized. For targeted medication delivery and in-flight monitoring, metal nanoparticles can have the surfaces functionalized with imaging and targeting ligands. They can also be used for photothermal therapy, which kills cancer cells by targeting them with heat instead of light (**Wilczewska et al. 2012**).

Liposomes for Targeted Therapy: The spherical vesicles known as liposomes are made of lipid bilayers and can encase a variety of compounds, including pharmaceuticals, in the aqueous

compartments. Due to the capacity to increase therapeutic efficacy and lessen adverse medication reactions, they have attracted considerable attention in the field of drug delivery. Numerous benefits of liposomes include the biocompatibility, biodegradability, and capacity to encapsulate both hydrophilic and hydrophobic medicines. The phospholipids and cholesterol that make up conventional liposomes give the lipid bilayer stability and mobility. These liposomes can also be divided into large unilamellar vesicles (LUVs) and small unilamellar vesicles (SUVs) according to the size. Although conventional liposomes have shown effective at delivering a variety of medications, they have drawbacks like quick bloodstream clearance and low accumulation at the target region. Long-circulating liposomes, also known as stealth liposomes, were created to address the drawbacks of ordinary liposomes (Zylberberg, C., & Matosevic, S. 2016).

Micelles for Targeted Drug Delivery: Micelles are colloidal structures made of amphiphilic block copolymers that self-assemble in aqueous liquids. These copolymers have segments that are both hydrophilic and hydrophobic. The hydrophilic blocks stay on the micelle's outside shell while the hydrophobic blocks gather in the center to form a stable nanostructure when it is submerged in water. Hydrophobic medications, which have problems with solubility and stability, can be effectively encapsulated in micelles because of the hydrophobic core. During or after micelle production, the drug molecules can be loaded into the hydrophobic core. By supplying steric hindrance and electrostatic repulsion, the hydrophilic shell of the micelles improves the stability and prevents aggregation.

Hydrogels as Targeted Drug Delivery Systems: Water or biological fluids can be absorbed and retained in huge quantities by hydrogels, which are three-dimensional crosslinked networks of hydrophilic polymers. Hydrogels have drawn a lot of interest as therapeutic drug delivery systems for targeted and sustained release because of the high-water content and soft, gel-like nature. Compared to traditional drug delivery systems, they have several benefits, including increased bioavailability, improved drug stability, and controlled release kinetics. Hydrogels come in two primary categories: natural and artificial hydrogels. Natural hydrogels come from biological materials including proteins (such as collagen and gelatin) and polysaccharides (such as alginate and hyaluronic acid). These hydrogels are excellent for a variety of biological applications because they frequently include inherent biocompatibility, biodegradability, and

bioactivity. Contrarily, synthetic hydrogels are produced by chemical processes and can be customized to fulfil unique needs (Lawrence, M. J., & Rees, G. D. 2012).

Challenges and Future Perspectives: Navigating the intricate regulatory environment is one of the biggest obstacles to the development of tailored medication delivery systems. With considerable preclinical and clinical evidence needed to prove safety and efficacy, the regulatory approval procedure for innovative drug delivery systems can be drawn out and rigorous. For researchers and developers, complying with these regulatory standards can be difficult because it calls for significant time, money, and skill commitments. The ability of drug delivery systems to scale is another issue. In the lab or small-scale investigations, it is possible to get encouraging results, but it can be challenging to apply those findings to manufacturing procedures that are carried out on a big scale. For targeted drug delivery systems to be successfully commercialized, consistency, repeatability, and quality control must be ensured throughout the scale-up process. Exciting possibilities exist for targeted medicine delivery thanks to nanotechnology. Researchers can create systems that enable real-time monitoring of medication release, distribution, and therapeutic response by combining imaging and diagnostic tools into nanoscale drug carriers. Personalized medical techniques are made possible by this integration, which improves precision and offers insightful feedback on treatment efficacy. By customizing therapies for individual patients, targeted drug delivery systems have the power to completely transform personalized medicine. Drug delivery systems can target diseased cells specifically while reducing off-target effects by using certain biomarkers or molecular signatures. With this strategy, treatment outcomes are enhanced, side effects are minimized, and therapeutic efficacy is increased (Ojewole et al. 2008).

Conclusion:

In conclusion, significant progress has been made in the creation and improvement of new drug delivery systems for targeted therapy since 2017. Significant developments in this area have revolutionized medicine delivery to body locations, increased therapeutic effectiveness, and reduced adverse effects. The use of nanotechnology-based systems, biomaterials, and intelligent drug carriers are just a few of the cutting-edge strategies that researchers have investigated to improve targeted medication delivery. These developments have made it possible to deliver therapeutic drugs precisely to cells or tissues, increasing medication concentration at the target

site while lowering exposure to healthy regions. In general, the creation and refinement of innovative drug delivery methods for targeted therapy hold enormous promise for personalized medicine and better patient outcomes. Future developments in this field of study, as well as those in nanotechnology and biomaterial science, will likely produce even more advanced and efficient drug delivery systems.

References:

- 1) Anselmo, A. C., & Mitragotri, S. (2014). An overview of clinical and commercial impact of drug delivery systems. *Journal of Controlled Release*, 190, 15-28.
- 2) Tacar, O., Sriamornsak, P., & Dass, C. R. (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. *Journal of pharmacy and pharmacology*, 65(2), 157-170.
- 3) Ojewole, E., Mackraj, I., Naidoo, P., & Govender, T. (2008). Exploring the use of novel drug delivery systems for antiretroviral drugs. *European Journal of Pharmaceutics and Biopharmaceutics*, 70(3), 697-710.
- 4) Zylberberg, C., & Matosevic, S. (2016). Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. *Drug delivery*, 23(9), 3319-3329.
- 5) Vyas, A., Saraf, S., & Saraf, S. (2008). Cyclodextrin based novel drug delivery systems. *Journal of inclusion phenomena and macrocyclic chemistry*, 62, 23-42.
- 6) Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012). Nanoparticles as drug delivery systems. *Pharmacological reports*, 64(5), 1020-1037.
- 7) Lawrence, M. J., & Rees, G. D. (2012). Microemulsion-based media as novel drug delivery systems. *Advanced drug delivery reviews*, 64, 175-193.
- 8) Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. *Journal of controlled release*, 148(2), 135-146.
- 9) Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017). Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. *Advanced drug delivery reviews*, 108, 25-38.

- 10) Karki, S., Kim, H., Na, S. J., Shin, D., Jo, K., & Lee, J. (2016). Thin films as an emerging platform for drug delivery. *asian journal of pharmaceutical sciences*, 11(5), 559-574.
- 11) Hirlekar, R. S., Patel, P. D., Dand, N., & Kadam, V. J. (2008). Drug loaded erythrocytes: as novel drug delivery system. *Current pharmaceutical design*, 14(1), 63-70.
- 12) Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., & Amin, A. F. (2009). Getting into the brain: approaches to enhance brain drug delivery. *CNS drugs*, 23, 35-58.
- 13) Alam, M., Mittal, A., & Chawla, D. (2017). Evaluating patients' perception towards generic and branded medicines: A segmentation approach. *Journal Of Generic Medicines*, 13(4), 184-192. doi: 10.1177/1741134317737925